Treatment
Carboplatin clinical trials
We’re tracking 493 recruiting studies that include Carboplatin, each written for real people, not researchers, below.
Recruiting studies
- NCT07642024RecruitingPhase 2/Phase 3
BL-B01D1 Plus Osimertinib Before Surgery for EGFR-Mutated Lung Cancer
This trial tests a combination of two drugs (BL-B01D1 and osimertinib) given before surgery to shrink EGFR-mutated lung tumors. The goal is to help make surgery more successful and improve outcomes for patients with this type of non-small cell lung cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07638852RecruitingPhase 2
Combining radiation and targeted drugs for triple-negative breast cancer brain tumors
This trial is testing whether giving radiation therapy along with a combination of chemotherapy (cisplatin or carboplatin), an immunotherapy drug called adebrelimab, and a drug called bevacizumab can better treat triple-negative breast cancer that has spread to the brain. The goal is to see if this combination can shrink or control the brain tumors and improve outcomes.
Shanghai, Shanghai MunicipalityAges 18–70 - NCT07632079RecruitingPhase 2
Fast-Track Radiation and Chemotherapy for Esophageal Cancer
This study tests a shorter course of combined radiation therapy and chemotherapy (using drugs called paclitaxel and carboplatin) to treat esophageal cancer with the goal of curing it. The faster treatment schedule may help patients finish therapy sooner while still being effective.
AmsterdamAges 18 years+ - NCT07625644RecruitingPhase 3
New immunotherapy combination for advanced lung cancer
This trial tests a new drug called BL-M14D1 combined with atezolizumab (an immunotherapy) against standard chemotherapy for extensive-stage small cell lung cancer, a serious type of lung cancer that has spread. The goal is to see if this combination helps patients live longer and control their cancer better.
Springdale, ArkansasAges 18 years+ - NCT07623356RecruitingPhase 1/Phase 2
Study of AK138D1 alone or with ivonescimab for advanced lung cancer
This trial tests an experimental drug called AK138D1, either by itself or combined with another drug (ivonescimab), for people with advanced non-small cell lung cancer that has spread. It aims to see if these treatments are safe and effective.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07622186RecruitingPhase 2
SKB571 combination therapy for advanced lung cancer
This trial tests a new drug called SKB571, given in combination with other treatments, for non-small cell lung cancer (a common type of lung cancer). The study aims to see if this combination helps shrink tumors and improve survival.
Beijing, Beijing MunicipalityAges 18–75 - NCT07624487RecruitingPhase 2
Aumolertinib and chemotherapy for EGFR L858R lung cancer
This trial tests a combination of aumolertinib (a targeted cancer drug) with chemotherapy in patients with advanced lung adenocarcinoma that has a specific genetic mutation called EGFR L858R. The goal is to see if this combination can slow or shrink the cancer better than existing treatments.
New Taipei CityAges 18 years+ - NCT07622797RecruitingPhase 2
Immunotherapy with chemotherapy and radiation for esophageal cancer
This trial tests a new immunotherapy drug (camrelizumab) combined with standard chemotherapy and radiation to treat advanced esophageal cancer while avoiding surgery if possible. The goal is to shrink the tumor and help you keep your esophagus working.
Luoyang, HenanAges 18 years+ - NCT06102824RecruitingPhase 2
Organoid-guided treatment for advanced breast cancer
This trial tests whether using a miniature version of your tumor grown in a lab can help choose the best treatment for advanced breast cancer. It compares this personalized approach to standard care.
Guangzhou, GuangdongAges 18–80 - NCT07595770RecruitingPhase 2
New immunotherapy combined with chemotherapy and radiation for esophageal cancer
This trial tests whether adding a new immunotherapy drug (adebrelimab) to standard chemotherapy and radiation improves outcomes for patients with esophageal squamous cell carcinoma before surgery. The goal is to shrink the tumor and improve survival.
Guangzhou, GuangdongAges 18–75 - NCT07601737RecruitingPhase 2
Nimotuzumab with immunotherapy and chemotherapy for head and neck cancer
This trial tests a combination of three treatments—nimotuzumab (a targeted therapy), a PD-1 inhibitor (which boosts your immune system), and chemotherapy—followed by surgery for locally advanced head and neck squamous cell carcinoma. The goal is to shrink the tumor and improve survival.
ShanghaiAges 18–75 - NCT07586202RecruitingPhase 2
Testing New Drug Combinations Before Lung Cancer Surgery
This trial tests whether giving new drugs (amivantamab plus either lazertinib or chemotherapy) before surgery helps people with a specific type of lung cancer that can be removed. The goal is to shrink tumors and improve surgery outcomes.
Duarte, CaliforniaAges 18 years+ - NCT07583550RecruitingPhase 2
Low-dose radiation followed by immunotherapy for extensive small cell lung cancer
This trial tests a combination of low-dose radiation to the chest, immunotherapy (adebrelimab), and chemotherapy for extensive-stage small cell lung cancer. The goal is to see if this approach can help control the cancer better than standard treatments and potentially improve outcomes.
Jiangmen, GuangdongAges 18–75 - NCT07559929RecruitingPhase 1/Phase 2
DXC006 with immunotherapy or chemotherapy for small cell lung cancer
This trial tests a new drug called DXC006, combined with either immunotherapy (checkpoint inhibitors) or platinum-based chemotherapy, for patients with small cell lung cancer. The goal is to see if this combination works better than standard treatments.
Guangzhou, GuangdongAges 18–75 - NCT07564141RecruitingPhase 3
New Drug for Recurrent Ovarian Cancer After Chemotherapy
This study tests a new medicine called Rina-S (with or without a blood vessel-blocking drug) compared to standard chemotherapy options for ovarian cancer that has come back after initial treatment. The goal is to see if Rina-S works better and is safer than current standard care.
Duarte, CaliforniaAges 18 years+ - NCT06467617RecruitingPhase 2
Immunotherapy and chemo before and after lung cancer surgery
This trial tests a combination of an immunotherapy drug (adebrelimab) plus chemotherapy and another drug (recaticimab) before and after surgery for people with stage II or III lung cancer that can be removed. The goal is to see if this approach helps shrink tumors and improves outcomes.
Beijing, Beijing MunicipalityAges 18–75 - NCT06735326RecruitingPhase 2
Fluzoparib and Bevacizumab Before Surgery for Advanced Ovarian Cancer
This trial tests whether combining fluzoparib (a PARP inhibitor) with or without bevacizumab (a blood vessel growth blocker) before surgery can shrink advanced ovarian cancer. It is for women with a BRCA gene mutation whose cancer cannot be fully removed with surgery right now.
Jinan, ShandongAges 18 years+ - NCT07544056RecruitingPhase 2/Phase 3
BEBT-209 Plus Chemotherapy for Triple-Negative Breast Cancer
This study tests a new drug called BEBT-209 combined with chemotherapy (carboplatin and gemcitabine) in women with advanced triple-negative breast cancer that has spread or cannot be surgically removed. The goal is to see if this combination can slow or stop cancer growth better than standard treatments.
Guangzhou, GuangdongAges 18–75 - NCT06532591RecruitingPhase 2
Cadonilimab plus chemo before and after lung cancer surgery
This trial tests a new immunotherapy drug (cadonilimab) combined with standard chemotherapy, given before and after surgery for lung cancer that has very low PD-L1. The goal is to see if this combination helps shrink the tumor and prevents it from coming back.
Chengdu, SichuanAges 18–70 - NCT07525869Recruiting
Pegfilgrastim to prevent low white blood cells in triple-negative breast cancer
This study tests whether a medicine called pegfilgrastim can help prevent dangerously low white blood cell counts in women with triple-negative breast cancer receiving a specific chemotherapy combination. Low white blood cells increase infection risk, so this medicine may help patients stay safer during treatment.
Seoul, Seodaemun-guAges 19–70 - NCT06480864Recruiting
Study of adebelimumab and apatinib for extensive stage small cell lung cancer maintenance
This trial tests whether adding two targeted therapies (adebelimumab, an immunotherapy, and apatinib, a drug that blocks blood vessel growth) after initial chemotherapy can help keep extensive stage small cell lung cancer under control. It is for people who have not yet had systemic treatment for their cancer and are in good enough health to try this maintenance approach.
Shenyang, LiaoningAges 18 years+ - NCT06755684RecruitingPhase 2
Pre-surgery targeted drug combo for EGFR-mutant lung cancer
This trial tests a new targeted pill (befotertinib) given before surgery, either with another targeted drug (bevacizumab) or with standard chemotherapy. The goal is to shrink the tumor and improve outcomes for people with a specific type of lung cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07502300RecruitingPhase 3
New drug combo for advanced small cell lung cancer
This trial tests a new drug combination (BL-B01D1 plus immunotherapy) as a first treatment for people with advanced small cell lung cancer. It may be an option if you haven't had treatment yet and are healthy enough for chemotherapy.
Zhengzhou, HenanAges 18 years+ - NCT07498907RecruitingPhase 3
Disitamab vedotin plus radiation for high-risk bladder cancer in kidney tube
This trial tests a targeted drug called disitamab vedotin combined with radiation after surgery for a rare type of bladder cancer in the upper urinary tract. It may be an option for people who cannot take standard chemotherapy because of kidney problems, hearing loss, or other health issues.
BeijingAges 18 years+
Common questions
- Are there clinical trials studying Carboplatin?
- Yes. Clin2 currently lists 493 recruiting studies that include Carboplatin, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Carboplatin trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Carboplatin an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Carboplatin or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.